Research programme: targeted immunotherapies - Kleo Pharmaceuticals

Drug Profile

Research programme: targeted immunotherapies - Kleo Pharmaceuticals

Alternative Names: Antibody recruiting molecules - Kleo Pharmaceuticals; ARMs - Kleo Pharmaceuticals; SyAMS - Kleo Pharmaceuticals; Synthetic antibody recruiting molecules - Kleo Pharmaceuticals

Latest Information Update: 06 Sep 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Yale University
  • Developer Kleo Pharmaceuticals
  • Class Immunotherapies; Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Infections

Most Recent Events

  • 01 Sep 2016 Kleo Pharmaceuticals and Biohaven Pharmaceuticals enter into a clinical development master service agreement for the development of targeted immunotherapies including Antibody Recruiting Molecules and Synthetic Antibody Recruiting Molecules
  • 01 Sep 2016 Targeted immunotherapies involving Antibody Recruiting Molecules (ARMs) and Synthetic Antibody Mimics licensed to Kleo Pharmaceuticals worldwide
  • 01 Sep 2016 Preclinical trials in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top